FindTrial
Sign In

A study to look at the role of calprotectin level in differentiating malignant from non malignant causes of accumulation of fluid in the pleural cavity

Pleural fluid calprotectin level in benign and malignant pleural effusion and its significance in predicting success of pleurodesis in malignant pleural effusion.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/04/032714
Enrollment
50
Registered
2021-04-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J90- Pleural effusion, not elsewhere classified

Interventions

None listed

Sponsors

DrAmartya Chakraborti
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients aged more than 18 years with undiagnosed pleural effusions and giving consent to participate in the study.

Exclusion criteria

Exclusion criteria: Pregnant females. Patients showing frank pus on the diagnostic thoracentesis.

Design outcomes

Primary

MeasureTime frame
To see association of pleural fluid calprotectin levels with the aetiology of pleural effusion.Timepoint: at time of thoracocentesis—

Secondary

MeasureTime frame
To find if any relationship exists between pleural fluid calprotectin levels and success rate of pleurodesis in patients with malignant pleural effusion.Timepoint: After pleurodesis—

Countries

India

Contacts

Public ContactDr Amartya Chakraborti

AIIMS Jodhpur Pulmonary medicine

nishant97@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026